Last reviewed · How we verify
MSC+ATG
At a glance
| Generic name | MSC+ATG |
|---|---|
| Also known as | Mesenchymal Stem Cells (Umbilical Cord Derived) |
| Sponsor | Chinese Academy of Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs (PHASE2)
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (PHASE2)
- Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (PHASE3)
- A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death (PHASE1)
- Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia (PHASE1,PHASE2)
- Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived） (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSC+ATG CI brief — competitive landscape report
- MSC+ATG updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI